grant
Purinergic Receptors in Myeloma
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Jan 2025Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2026ATF6ATF6 geneActivating Transcription Factor 6AcuteAntibodiesApoptosisApoptosis PathwayAssayAutoregulationB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor GeneB-Cell Differentiation Factor-2B-Cell Stimulatory Factor 2 GeneB-Cell Stimulatory Factor-2BCDFBCL2L11BCL2L11 geneBIMBIMELBIMLBSF-2BSF-2 GeneBSF2BSF2 GeneBeta-2 Gene InterferonBimMELBioassayBiochemistryBiologic ModelsBiological AssayBiological ChemistryBiological ModelsBiologyBlood Plasma CellBone MarrowBone Marrow Reticuloendothelial SystemCancersCationsCause of DeathCell BodyCell Communication and SignalingCell DeathCell Death InductionCell SignalingCell SurvivalCell ViabilityCellsCessation of lifeCommunicating JunctionConnexinsDNA mutationDataDeathDependenceDevelopmentER stressElementsEventFamilyFc ReceptorFosteringGap Junction ProteinsGap JunctionsGene TranscriptionGeneralized GrowthGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGrowthHPGFHSF GeneHepatocyte Stimulatory Factor GeneHepatocyte-Stimulating FactorHomeostasisHumanHybridoma Growth FactorHybridoma Growth Factor GeneIFN-beta 2IFNB2IFNB2 GeneIL-6IL-6 GeneIL6IL6 ProteinIL6 geneIn SituIn VitroInduction of ApoptosisInterleukin 6 (Interferon, Beta 2) GeneInterleukin-6Interleukin-6 GeneIntracellular Communication and SignalingKnowledgeLifeLife ExperienceLow-resistance JunctionMGI-2MGUSMalignantMalignant - descriptorMalignant NeoplasmsMalignant TumorMiceMice MammalsModel SystemModelingModern ManMonoclonal Gammopathy of Undetermined SignificanceMonoclonal Gammopathy of Unknown SignificanceMonoclonal gammopathy of uncertain significanceMultiple MyelomaMurineMusMutateMutationMyeloid Differentiation-Inducing ProteinNewly DiagnosedNexus JunctionOsteoblastsPDX modelPathogenicityPathway interactionsPatient derived xenograftPatientsPhysiological HomeostasisPlasma Cell DyscrasiaPlasma Cell NeoplasmPlasma Cell TumorPlasma CellsPlasma-Cell MyelomaPlasmacytesPlasmacytic NeoplasmPlasmacytic TumourPlasmacytoma Growth FactorPoisonProgrammed Cell DeathProteasome InhibitorProtein BiosynthesisProteinsPurine ReceptorsPurinergic ReceptorsPurinoceptorRNA ExpressionReceptor ProteinReceptor SignalingRecurrent diseaseRegulationRegulatory PathwayRelapseRelapsed DiseaseRibosomal Peptide BiosynthesisRibosomal Protein BiosynthesisRibosomal Protein SynthesisRibosomesRoleSignal TransductionSignal Transduction SystemsSignalingSocial Support SystemSupport SystemSystemTestingTissue GrowthToxic ChemicalToxic SubstanceTranscriptionTransgenesTranslationsTumor BurdenTumor LoadXBP1XBP1 geneadvanced diseaseadvanced illnessantibody receptorbiological signal transductionbonechemotherapydevelop therapydevelopmentalendoplasmic reticulum stressexperienceextracellulargenome mutationimproved outcomeinhibitorinsightinterferon beta 2intervention developmentmalignancymouse modelmurine modelmyelomamyelomatosisnecrocytosisneoplasm/cancernew approachesnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel approachesnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetontogenypathwaypatient derived xenograft modelplasmocyteprecancerprecancerouspremalignantpreventpreventingprotein homeostasisprotein synthesisproteostasisreceptorsocial roletherapy developmenttoxic compoundtransgenetranslationtreatment development
Description preview
Project summary
The purpose of this project is to identify novel regulators of ER homeostasis in malignant
plasma cells that can be targeted to induce the death of these cells and/or prevent
upstream events that foster plasma cell malignancy. Our focus is multiple myeloma (MM),
a deadly malignancy of antibody-secreting plasma cells that typically…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click